ChromaDex (NASDAQ:CDXC) Stock Crosses Above 200 Day Moving Average of $1.88

ChromaDex Co. (NASDAQ:CDXC)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.88 and traded as high as $3.72. ChromaDex shares last traded at $2.95, with a volume of 877,796 shares traded.

Wall Street Analysts Forecast Growth

CDXC has been the subject of a number of research reports. StockNews.com initiated coverage on shares of ChromaDex in a research report on Sunday, March 3rd. They set a “strong-buy” rating for the company. Roth Mkm increased their target price on shares of ChromaDex from $4.25 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th.

ChromaDex Price Performance

The stock has a market capitalization of $222.16 million, a PE ratio of -42.14 and a beta of 1.98. The business’s fifty day moving average price is $2.74 and its 200-day moving average price is $1.88.

Institutional Investors Weigh In On ChromaDex

A number of institutional investors and hedge funds have recently modified their holdings of CDXC. Tieton Capital Management LLC lifted its holdings in shares of ChromaDex by 18.8% in the fourth quarter. Tieton Capital Management LLC now owns 2,913,675 shares of the company’s stock worth $4,167,000 after buying an additional 461,692 shares in the last quarter. Silverberg Bernstein Capital Management LLC purchased a new stake in shares of ChromaDex in the fourth quarter worth about $118,000. Gamco Investors INC. ET AL lifted its holdings in shares of ChromaDex by 26.5% in the third quarter. Gamco Investors INC. ET AL now owns 259,850 shares of the company’s stock worth $379,000 after buying an additional 54,500 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of ChromaDex by 121.9% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,031 shares of the company’s stock worth $121,000 after buying an additional 45,618 shares in the last quarter. Finally, Gabelli Funds LLC lifted its holdings in shares of ChromaDex by 9.1% in the third quarter. Gabelli Funds LLC now owns 180,000 shares of the company’s stock worth $263,000 after buying an additional 15,000 shares in the last quarter. 15.41% of the stock is owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.